Company news
Phathom Pharmaceuticals, Inc. news in 2023
Phathom Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 13, 2023
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 5, 2023
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 27, 2023
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 8, 2023
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
October 31, 2023
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 29, 2023
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 25, 2023
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 20, 2023
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
August 9, 2023
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 11, 2023
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
June 8, 2023
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
May 22, 2023
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 22, 2023
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 22, 2023
Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 9, 2023
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
May 8, 2023
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
April 3, 2023
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
Phathom Pharmaceuticals Provides Regulatory Updates
February 8, 2023
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 7, 2023
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
January 2, 2023